262 results about "Cerebral injury" patented technology

The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

The invention relates to hand function rehabilitation training equipment based on a spontaneous movement imagery electroencephalograph. Hardware of the instrument consists of an electroencephalograph signal acquisition and processing module, a hand force signal real-time detection sensor array, a control module based on multisource information fusion and a rehabilitation manipulator module, and software for supporting the active rehabilitation training of hand functions is arranged in a computer. The rehabilitation training equipment provides external compensation assistance or resistance hierarchically by taking movement imagery electroencephalographs of patients who suffer from cerebral injury as a starting signal and the muscle force of hands as a feedback signal in a self-adaptive mode according to the myasthenia state of the patients to assist patients who suffer from dyskinesia in performing passive, assisted and active rehabilitation training, displays the state information of the hand movement functions and the provided external power information for doctors and the patients and provides an objective and quantitative assessment method and an index for clinical rehabilitation diagnosis and treatment. The instrument is easy to use, has a friendly interface and is accepted by the doctors and the patients easily. A user can operate a system of the instrument without programming experiences, and the operating environment is not complex.

The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. In a particular aspect, patient samples are analyzed for the presence or amount of a panel of markers comprising one or more specific markers for cerebral injury and one or more non-specific markers for cerebral injury. In an alternative aspect, samples are analyzed for B-type natriuretic peptide. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

The invention provides a pharmaceutical composition useful in treating cerebral ischemia and cerebral injury. The pharmaceutical composition is also useful as a prophylactic treatment during surgical procedures wherein the potential for ischemic tissue damage is present. Also included in the invention is a method for preparing the pharmaceutical composition, as well as methods for treatment.

The disclosure provides compositions treating traumatic brain injuries such as concussions. In one embodiment, the composition comprises phosphatidylserine, phosphatidylcholine, quercetin, astaxanthin, R-alpha lipoic acid, N-acetyl cysteine, taurine, L-glutamine, carnitine, D-ribose, creatine, epigallocatechin gallate, melatonin, ginkgo leaf extract, curcumin and L-glycine. The disclosure also provides methods for treating traumatic brain injuries such as concussions by administering an effective amount of the compositions described within.

The present invention relates to the field of biomarkers. More specifically, the present invention relates to biomarkers useful in diagnosing brain injuries. Brain injury can include overt or traumatic brain injury, as well as subclinical brain injury (SCI). In one embodiment, a method for diagnosing SCI in a patient comprises (a) collecting a sample from the patient; (b) measuring the levels of a panel of biomarkers in the sample collected from the patient, wherein the panel of biomarkers comprises ASTN1, BAI3, CNDP1, ERMIN, GFAP, GRM3, KLH32, MAGE2, NRG3, NRGN, OMG, SLC39A12, RTN1, and MT3; and (c) comparing the levels of the panel of biomarkers with predefined levels of the same panel of biomarkers that correlate to a patient having SCI and predefined levels of the same panel of biomarkers that correlate to a patient not having SCI, wherein a correlation to one of the predefined levels provides the diagnosis.

The present invention provides minimally invasive methods of detecting, diagnosing, and assessing neuronal damage associated with traumatic brain injury (TBI) or chronic traumatic encephalopathy (CTE). Specific species of microRNAs (miRNA), small, noncoding RNA molecules that play gene regulatory functions, are correlated with cellular damage and oxidative stress following TBI or CTE, allowing for rapid, minimally-invasive diagnosis and assessment of brain injury. The early identification and longitudinal assessment of neuronal damage in subjects suffering from or at risk of suffering from a TBI (e.g., football players, boxers, military personnel, fall victims) will improve clinical outcomes by guiding critical medical and behavioral decision making.

The invention provides a pharmaceutical composition useful in treating cerebral ischemia and traumatic cerebral injury. The pharmaceutical composition is also useful as a prophylactic treatment during surgical procedures wherein the potential for ischemic tissue damage is present. Also included in the invention is a method for preparing the pharmaceutical composition, as well as methods for treatment.

Methods and apparatuses for sensory electrical stimulation of the peripheral nervous system to improve human motor function and performance are described. Methods and devices may be used to enhance physical performance of athletes, professionals, and gamers or improve motor function (hand, finger and limb movement) in patients rehabilitating from neurological deficits and impairments caused by stroke, traumatic brain injury and other neurologic or non-neurologic conditions. These apparatuses and methods may be used for physical training and mental training (to improve memory and functional performance including motor coordination, limb-eye coordination, occupational and recreational skills) through periodic or sustained sensory electrical stimulation. Treatment plans may be based on biomarkers and may be used alone or in combination with other apparatuses. Learning and feedback techniques individualize treatment parameters depending on the subject's neurologic and motor function in diseased patients and healthy users.

The present invention discloses achyranthes bidentata polypeptide, a production method and applications, and the achyranthes bidentata polypeptide is produced with the steps including polypeptide extraction, polypeptide separation, etc. The achyranthes bidentata polypeptide is used to the preparation of drugs and health products for treating peripheral nerve injuries, cerebrovascular accidents, ischemic brain injuries, cerebral traumas, optic nerve injuries, spinal cord injuries and central nervous system injuries, antiaging and preventing neurodegenerative diseases. Experiments prove that the extracted achyranthes bidentata polypeptide (protein) of the present invention has the effects of promoting the growth of nerves, preventing the fading of nerve cells and promoting the regeneration of injured nerves, the source of medicinal materials is single, the preparation method is advanced, the technique is reasonable, the ingredients of preparations are definite, safety is high, and pharmacological action is obvious.

Virtual Reality systems may be used in healthcare and therapy, e.g., focusing on physical and neurorehabilitation. For instance, victims of brain injury may seek treatment to improve, e.g., range of motion, balance, coordination, joint mobility, flexibility, posture, endurance, and strength. VR systems can be used to entertain and instruct patients in their movements while recreating practical exercises to further therapeutic goals. Patient movement data during physical therapy sessions may be valuable to patients and healthcare practitioners. The system may comprise a plurality of body sensors, a VR headset, and a supervisor tablet. The disclosed system may facilitate translation between real world coordinates and virtual world coordinates, assigning sensors to body parts, measuring range of motion of joints and limbs, correcting sensor orientation, recording and presenting therapy data, and generating and animating a 3-D virtual reality avatar in a virtual world to perform activities, among other benefits.

The medicine for treating cardiac and cerebral vascular diseases and blood supply insufficiency has the material composition of eight kinds of Chinese medicinal materials, including glossy ganoderma, gingko leaf, epimedium, kudzu vine root, Chuanxiong rhizome, etc. It may be prepared into various orally taken preparations and injection ppns. The medicine has the functions of benefiting vital energy, promoting blood circulation to disperse blood clots, dredging meridian, etc. and has obvious curative effect on cerebral injury, apoplexy, coronary diseases, blood supply insufficiency and other cardiac and cerebral vascular diseases.

The invention relates to a method for establishing an artery ischemia model of a brain of a rhesus monkey and an evaluation method. The constructing method adopts the mode of directly puncturing femoral arteries of an experimental monkey to perform the intravascular interventional operation under the direct view of a digital subtraction angiography, and establishes the chronic cerebral infarctionprimate model by using a micro-catheter to block the arteries in the brain of the experimental monkey and controlling ischemia time. The model is a quite reasonable cerebral ischemia-reperfusion animal model, and the pathological characteristics of the monkey cerebral injury model established by the method are similar to clinical manifestation; and moreover, the model is stable and reliable and issuitable for all kinds of curing therapeutic research and related basic research.

The invention belongs to the technical field of nutritional healthcare food and particularly relates to an ocean polypeptide food for special dietary use and capable of promoting intelligence development. The food for special dietary use comprises the following raw materials in parts by weight: 5.0-15.0 parts of ocean oligopeptide, 1.5-2.0 parts of ocean bioactive polysaccharides, 1.5-2.0 parts of seaweed meal, 1.5-2.5 parts of nutritional amino acid, 1.5-2.5 parts of oligosaccharide, 0.2-0.8 part of nutrient, 0.03-0.10 part of vitamin, 0.2-0.8 part of mineral substance, 5.0-10.0 parts of bifidobacterium, 5.0-10.0 parts of lactobacillus, 2.0-5.0 parts of semen juglandis powder, 2.0-5.0 parts of Chinese yam powder, 2.0-3.0 parts of American ginseng powder and 2.0-3.0 parts of lucid ganoderma powder. The raw materials adopted in the invention are high in safety; the long-term eating of the food is free from side effect; the food is capable of promoting the memory of children and old people and guaranteeing the brain vitality and has an excellent therapeutic function for mental retardation and cerebral injury of the children.

The present invention relates to the detection of traumatic brain injury by detecting Aβ protein aggregates associated with traumatic brain injury. These Aβ protein aggregates are detected using peptide and peptide mimic probes that preferentially associate with Aβ protein aggregates associated with traumatic brain injury.

The invention relates to a fluorescent immunochromatographic test strip capable of rapid GFAP detection and preparation and application of the test strip. The test strip comprises a base plate, and asample pad, a bonder release pad, a chromatographic film and a water absorption pad arranged along the length direction of the base plate respectively; the chromatographic film is provided with a detection line and a quality control line separate from the detection line; a fluorescent probe of a GFAP monoclonal antibody marked by fluorescent microballoons is fixed on the bonder release pad; the detection line is coated with a GFAP antigen paired with the microballoon mark antibody; and the quality control line is coated with an IgG antibody. Compared with the prior art, the fluorescent immunochromatographic test strip capable of rapid GFAP detection is prepared by preparing the GFAP recombined antigen and monoclonal antibody and combining a time resolved fluorescence lateral immunochromatography technique; and a method for rapidly detecting a cerebral injury marker GFAP in serum is formed, so that the concentration of GFAP in the human serum can be detected rapidly and quantitatively.

The invention discloses a preparation method and an application of human umbilical cord mesenchymal stem cells. The preparation method includes the steps of: performing asepsis treatment to umbilical cord of a full-term caesarean delivered healthy fetus, mechanically cutting the umbilical cord, digesting the umbilical cord through collagenase and performing separation cultivation. In about the third generation, cell shape becomes flat and broad and the cells grow well. The method can culture the cells till the 15th generation, wherein cell division phase is reduced and cytoplasm is loose, there are vacuoles in the cells, and cell aging and proliferation are significantly slowed, so that the third-generation cells have high activity and can be applied in subsequent researching and treatment. The human umbilical cord mesenchymal stem cells are used in therapy of cerebral injury, and improve function recovery after the cerebral injury.